

***Plasmodium falciparum*, Strain Cam5\_rev**

**Catalog No. MRA-1253**

**Product Description:** *Plasmodium falciparum* (*P. falciparum*), strain Cam5\_rev is a K13-propeller revertant mutant of the original Cam5 strain, featuring a reversion in wild-type allele I543T. The original Cam5 strain (also referred to as IPC 4912), was isolated in 2011 from a human patient with malaria in Mondulkiri province, eastern Cambodia. *P. falciparum*, strain Cam5\_rev was deposited as susceptible to artemisinin.

**Lot<sup>1</sup>: 63268023**

**Manufacturing Date: 20FEB2015**

TEST	SPECIFICATIONS	RESULTS
<b>Identification by Giemsa Stain Microscopy<sup>2</sup></b>	Blood-stage parasites present	Blood-stage parasites present
<b>Antimalarial Susceptibility Profile (<i>in vitro</i>)</b> Half-maximal Inhibitory Concentration (IC <sub>50</sub> ) by SYBR green I <sup>®</sup> drug sensitivity assay <sup>3</sup> Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine Ring-stage Survival Assay (RSA <sub>0-3h</sub> ) <sup>4</sup> Dihydroartemisin (DHA) <sup>5</sup>	Report results Report results Report results Report results Report results Report results Report results	23.7 ± 1.6 nM 6.1 ± 0.6 nM 176.3 ± 20.3 nM 571.4 ± 119.3 nM 19050 ± 3976.1 nM 221700 ± 51500 nM
<b>Genotypic Analysis</b> Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 710 base pairs) MSP2 PCR amplicon analysis <sup>6</sup>	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon	Consistent with <i>P. falciparum</i> (Figure 1) ~ 900 base pair amplicon (Figure 2)
<b>Level of Parasitemia</b> Pre-freeze <sup>7</sup> Post-freeze <sup>8</sup>	Report results > 1%	3.25% 2.48%
<b>Viability (post-freeze)<sup>9</sup></b>	Growth in infected red blood cells	Growth in infected red blood cells
<b>Sterility (21-day incubation)</b> Harpo's HTYE broth <sup>10</sup> , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
<b>Mycoplasma Contamination</b> DNA Detection by PCR	None detected	None detected

<sup>1</sup>MRA-1253 was produced by cultivation of the deposited material in fresh human erythrocytes in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N<sub>2</sub>, 5% CO<sub>2</sub>, 5% O<sub>2</sub>) and monitored for parasitemia daily for 8 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

<sup>2</sup>Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 1 day.

<sup>3</sup>A SYBR Green I<sup>®</sup> anti-malarial drug sensitivity assay in 96-well plates was used to determine IC<sub>50</sub> values of an active (> 70% ring stage) parasite

culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I<sup>®</sup>-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.mr4.org/Publications/MethodsInMalariaResearch.aspx>].

<sup>4</sup>A detailed RSA<sub>0-3h</sub> protocol is available on the Worldwide Antimalarial Resistance Network's website at <http://www.wwarn.org/tools-resources/procedures/ring-stage-survival-assays-rsa-evaluate-vitro-and-ex-vivo-susceptibility>.

<sup>5</sup>*P. falciparum*, strain Cam5\_rev was reported with a DHA RSA<sub>0-3h</sub> value of 0.3% [Straimer, J., et al. "Drug Resistance. K13-Propeller Mutations Confer Artemisinin Resistance in *Plasmodium falciparum* Clinical Isolates." *Science* 347 (2015): 428-431. PubMed: 25502314].

<sup>6</sup>Primer sequences and conditions for PCR are available upon request.

<sup>7</sup>Pre-freeze parasitemia was determined after 8 days post infection by microscopic counts of Giemsa-stained blood smears.

<sup>8</sup>Post-freeze parasitemia was determined after 1 day post infection by microscopic counts of Giemsa-stained blood smears.

<sup>9</sup>Viability was confirmed by examination of infected erythrocytes for parasitemia (2.48%) at 1 day post infection.


<sup>10</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

**Figure 1: MRA-1253 MSP2 Sequence**

```

TTTATTTATT GAAGCAATAT TACTAGAGTT ATTTAAGAGG GATGTTGCTG CTCCACAGTT TTCTTTGTTA CCATCGGTAC
ATTCTTTTTG ACTATCAGAA GTATTTTGTG GATGATTATT TCTAGAACCA TGCATATGTC CATGTTGTCC TGTACCTTTA
TTCTCTGGTG CAGCAGGATT TTCATTTTCT GCCGTTTGGG GTTCTTGTGG AGCTTTGGGT CCTTCTCAG TTGATTCATT
TAATTCATTT TGTTTTTTAC TCTCTTCTCC TTTACCGTTT GTTTTATTTG GTGCATTGCC AGAACTTGAA CTTTCTGTAG
TAGTGATGGG TGGTGAAGGT GAATTACTTT CTGTAGTAGT GATGGGTGGT GAAGGTGAAT TACTTCTGT AGTAGTGATG
GGTGGTGAAG GTGAATTACT TTCTGTAGTA GTGATGGGTG GTGAAGGTGA ATTACTTTTT GTAGCAGTAG GGGTATCAGC
AGCGGTAGGA GTAGTAGTTT GTGATTCTCC ATTATTAGTA GTACTAGTAC TTGCCTATT TGTACTACTT TGACTTCCAC
TAGCAATAGT ATCAGCATTT GGAGCATTTG CACCTACACT AGTAGTATTA GAACCTTCAT TTGCCATACT TCTCCTTATA
CTCATATTAT AAGCATTGTT TATGAATGTG TTGCTATATT TACTTTCATT TTTAATATTA AAGGTAAC
    
```

**Figure 2: PCR Amplification of MSP2**



Lane 1: Invitrogen™ TrackIt™ 100 bp DNA ladder  
 Lane 2: 100 ng of MRA-1253

Date: 03 DEC 2015

Signature:

BEI Resources Authentication

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

